NUVB

Nuvation Bio Inc - Ordinary Shares - Class A

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of...

Nuvation Bio to Participate in Upcoming Investor Conferences Nuvation Bio to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, May 5, 2026 NEW YORK, May 5, 2026 /PRNewswire...

Royal Bank Of Canada reaffirmed an 'outperform' rating and set a $20.00 target price on shares of Nuvation Bio in a report on Tuesday...

Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Nuvation Bio in a research report on Tuesday...

Nuvation Bio (NYSE:NUVB) executives said the company made continued commercial progress with ROS1-positive non-small cell lung cancer (NSCLC) therapy Ibtrozi during the first quarter of 2026...

Nuvation Bio (NUVB) delivered earnings and revenue surprises of -91.30% and +0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Nuvation Bio (NYSE:NUVB - Get Free Report) issued its earnings results on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.04. The business had revenue of $83.23 million for the quarter, compared to analyst estimates of...

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire NEW YORK, May...

Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a ho...